MiMedx's strategic realignment to focus on its Wound & Surgical business is expected to improve operating margins and free cash flow generation. The suspension of the Knee Osteoarthritis program and disbanding of the Regenerative Medicine unit will result in one-time wind-down expenses of $5 million, but the company expects an addition of $25 million of Adjusted EBITDA for FY23. This news, along with the raised 2023 net sales growth outlook, has led to a positive short-term impact on the stock price, with shares up 4.79% premarket.